250 related articles for article (PubMed ID: 25516553)
1. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
[TBL] [Abstract][Full Text] [Related]
2. HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?
Marra CM
Antivir Ther; 2015; 20(4):365-7. PubMed ID: 25781980
[TBL] [Abstract][Full Text] [Related]
3. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
[TBL] [Abstract][Full Text] [Related]
5. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
[TBL] [Abstract][Full Text] [Related]
6. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
[TBL] [Abstract][Full Text] [Related]
7. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.
Smurzynski M; Wu K; Letendre S; Robertson K; Bosch RJ; Clifford DB; Evans S; Collier AC; Taylor M; Ellis R
AIDS; 2011 Jan; 25(3):357-65. PubMed ID: 21124201
[TBL] [Abstract][Full Text] [Related]
8. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
Pou C; Noguera-Julian M; Pérez-Álvarez S; García F; Delgado R; Dalmau D; Álvarez-Tejado M; Gonzalez D; Sayada C; Chueca N; Pulido F; Ibáñez L; Rodríguez C; Casadellà M; Santos JR; Ruiz L; Clotet B; Paredes R
Clin Infect Dis; 2014 Aug; 59(4):578-88. PubMed ID: 24879788
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
[TBL] [Abstract][Full Text] [Related]
10. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
Cross HM; Combrinck MI; Joska JA
S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
[TBL] [Abstract][Full Text] [Related]
11. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M; Prosperi M; Vicenti I; Di Giambenedetto S; Callegaro A; Bruzzone B; Baldanti F; Gonnelli A; Boeri E; Paolini E; Rusconi S; Giacometti A; Maggiolo F; Menzo S; De Luca A;
J Antimicrob Chemother; 2009 Sep; 64(3):616-24. PubMed ID: 19620134
[TBL] [Abstract][Full Text] [Related]
12. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
Gonzalez-Serna A; Glas AC; Brumme CJ; Poon AF; Nohpal De La Rosa A; Mudrikova T; Dias Lima V; Wensing AM; Harrigan R
J Antimicrob Chemother; 2017 Feb; 72(2):496-503. PubMed ID: 27999069
[TBL] [Abstract][Full Text] [Related]
13. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score.
Kahouadji Y; Dumurgier J; Sellier P; Lapalus P; Delcey V; Bergmann J; Hugon J; Paquet C
HIV Med; 2013 May; 14(5):311-5. PubMed ID: 23035982
[TBL] [Abstract][Full Text] [Related]
14. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
Bogoch II; Davis BT; Venna N
J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
[TBL] [Abstract][Full Text] [Related]
15. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
[TBL] [Abstract][Full Text] [Related]
16. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.
Casado JL; Marín A; Moreno A; Iglesias V; Perez-Elías MJ; Moreno S; Corral I
J Neurovirol; 2014 Feb; 20(1):54-61. PubMed ID: 24420449
[TBL] [Abstract][Full Text] [Related]
18. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
Garvey L; Surendrakumar V; Winston A
HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals.
Baker LM; Paul RH; Heaps-Woodruff JM; Chang JY; Ortega M; Margolin Z; Usher C; Basco B; Cooley S; Ances BM
J Neuroimmune Pharmacol; 2015 Sep; 10(3):487-92. PubMed ID: 25900078
[TBL] [Abstract][Full Text] [Related]
20. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM
Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
